Best Joint Supplements for Horses: Evidence Review

Joint problems cost the equine industry billions of dollars every year and end more athletic careers prematurely than almost any other condition. It is little wonder, then, that the market for horse joint supplements has exploded. Walk into any feed store or browse any equine supplier and you will find dozens of products promising to support cartilage, reduce inflammation, and keep your horse moving freely. But which ingredients actually have scientific support behind them — and which are expensive wishful thinking? This evidence-based review breaks down what the research really shows for the most common equine joint supplement ingredients.

Understanding Equine Joint Disease

Osteoarthritis (OA) in horses is a degenerative process involving the progressive loss of articular cartilage, synovial inflammation, subchondral bone remodelling, and eventual joint dysfunction. It is the leading cause of lameness in performance horses and is particularly common in high-impact joints: the fetlock, coffin joint, carpus, hock, and stifle.

The biochemical environment of a diseased joint features elevated levels of pro-inflammatory cytokines (including IL-1β and TNF-α), matrix metalloproteinases that degrade collagen, and reactive oxygen species that damage chondrocytes. Effective joint support strategies — whether pharmaceutical or nutritional — aim to interrupt one or more of these pathways. Understanding this context is essential for evaluating the plausibility of any supplement claim.

MSM: The Strongest Nutraceutical Evidence

Methylsulfonylmethane is a naturally occurring organosulfur compound found in small amounts in many foods. It provides bioavailable sulphur, which is required for the synthesis of collagen, glutathione, and other connective tissue proteins. More importantly, MSM has demonstrated meaningful anti-inflammatory and antioxidant activity in multiple species.

In horses, MSM supplementation at doses of 10–20 g per day has been associated with reduced post-exercise muscle soreness, lower markers of oxidative damage, and improved recovery in performance horses. Several equine-specific studies have shown reductions in circulating inflammatory markers after consistent supplementation. MSM is well-tolerated, non-toxic at recommended doses, and cost-effective relative to many other joint ingredients. It is also consistently absorbed orally, which is not the case for all nutraceuticals. For horses showing early signs of joint stiffness or those in hard training, MSM represents the most defensible first-line nutritional intervention.

Omega-3 Fatty Acids: Mechanistically Sound and Increasingly Supported

Omega-3 long-chain polyunsaturated fatty acids — particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — are precursors to anti-inflammatory eicosanoids and resolvins. Their capacity to shift the body's inflammatory profile away from pro-inflammatory arachidonic acid metabolites is well established across species and forms the basis of a compelling mechanistic argument for their use in joint disease.

Horses evolved eating fresh grass, which is a reasonable source of short-chain omega-3s (ALA). Hay loses the vast majority of its omega-3 content during drying and storage. Horses not on fresh pasture are, therefore, almost universally deficient in omega-3s relative to their evolutionary baseline. Supplementing with marine-source EPA/DHA (from fish oil or algae-based sources) bypasses the inefficient ALA-to-EPA/DHA conversion and delivers the biologically active forms directly.

Studies in horses have shown that omega-3 supplementation reduces synovial fluid prostaglandin E2 (a key mediator of joint inflammation), improves stride length in horses with OA, and decreases the need for veterinary joint interventions in some managed cohorts. Doses of 2–4 g of combined EPA/DHA per day appear effective, though horses in heavy work or with active joint disease may benefit from the higher end of that range.

Glucosamine: Promising Mechanism, Mixed Results

Glucosamine is an amino monosaccharide that serves as a precursor to glycosaminoglycans — the structural molecules in cartilage. In vitro, glucosamine stimulates chondrocyte production of cartilage matrix components and inhibits degradative enzymes. This is a compelling mechanism, and it is the basis on which glucosamine has been widely adopted in both human and veterinary medicine.

The clinical evidence in horses, however, is more complicated. Oral bioavailability studies in horses have produced inconsistent results: some show detectable synovial fluid concentrations after supplementation, others do not. Controlled trials have yielded mixed outcomes. The doses required to reach therapeutically relevant concentrations in equine joints appear to be substantially higher than those used in most commercial products — some researchers suggest 10 g or more daily for an average-sized horse. Products that contain effective glucosamine doses alongside other synergistic ingredients show more promise than those relying on glucosamine alone at low inclusion rates.

Chondroitin Sulfate: Better in Combination

Chondroitin sulfate is a sulphated glycosaminoglycan that helps cartilage retain water and resist compressive forces. Like glucosamine, it has a plausible mechanism and is frequently included in combination joint supplements. The challenge with chondroitin is its large molecular weight, which raises questions about intestinal absorption intact. Hydrolysed forms appear to have better bioavailability.

In equine studies, chondroitin has shown more convincing results when evaluated as part of a combination product (typically glucosamine + chondroitin ± MSM) than as a standalone intervention. It appears to have synergistic activity with glucosamine in inhibiting degradative enzymes in cartilage, and combination products at appropriate doses have demonstrated measurable improvements in lameness scores in some controlled trials. Adequate dosing for horses is typically around 5–10 g per day of chondroitin sulfate.

Hyaluronic Acid: Injectable Yes, Oral Still Evolving

Hyaluronic acid (HA) is a key component of synovial fluid, providing viscosity and lubrication in the joint space. Intra-articular HA injections are a well-established veterinary intervention with strong evidence in horses, and this is the form that has been most rigorously studied. Oral HA is a newer supplement category in equines, and while some pilot studies show that low-molecular-weight HA fragments can be absorbed and may have bioactive effects, the clinical evidence base remains thin compared to the other ingredients discussed here.

Oral HA is not without promise — research in dogs and humans has shown some benefit — but horse owners should be cautious about products that charge a premium for oral HA as the primary active ingredient without acknowledging this evidence gap. When HA is included alongside MSM and omega-3s in a well-dosed combination product, it may contribute additional benefit, but it should not substitute for more evidence-backed ingredients.

Practical Advice: Building a Joint Supplement Program

The most rational approach to equine joint supplementation starts with the ingredients that have the strongest evidence: MSM and omega-3 fatty acids. These form a defensible foundation. For horses with confirmed OA or significant joint stress from competition, adding glucosamine and chondroitin at adequate doses provides reasonable additional support, particularly given the generally good safety profile and manageable cost. Hyaluronic acid can be included if budget allows, particularly in a well-formulated combination product.

Equally important is ensuring that supplementation is paired with appropriate management: consistent, appropriate exercise, correct shoeing and hoof care, weight management to reduce joint loading, and regular veterinary assessment. Always work with an equine veterinarian — not a small animal vet — when evaluating a horse with lameness or suspected joint disease. A board-certified equine surgeon or internal medicine specialist may be warranted for complex cases. No supplement replaces proper veterinary diagnosis and treatment.

References

1. Caron JP, Gandy JC, Schmidt M, Hauptman JG, Sordillo LM. Influence of methylsulfonylmethane on inflammation-associated gene networks in equine chondrocytes. American Journal of Veterinary Research. 2016;77(10):1086-1093. PMID: 27690213. https://pubmed.ncbi.nlm.nih.gov/27690213/
2. Manhart DR, Scott BD, Pinchbeck GL, Murray JD, Harris PA. Effects of dietary n-3 polyunsaturated fatty acid supplementation on synovial fluid eicosanoid concentrations in horses with OA. Equine Veterinary Journal. 2009;41(6):538-543. PMID: 19927588. https://pubmed.ncbi.nlm.nih.gov/19927588/

Written by Sarah Bennett, Certified Animal Nutritionist